A Comparative Analysis of SARS-CoV-2 Antivirals Characterizes 3CL(pro) Inhibitor PF-00835231 as a Potential New Treatment for COVID-19

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiological agent of coronavirus disease 2019 (COVID-19). There is a dire need for novel effective antivirals to treat COVID-19, as the only approved direct-acting antiviral to date is remdesivir, targeting the viral polymerase comp...

Descripción completa

Detalles Bibliográficos
Autores principales: de Vries, Maren, Mohamed, Adil S., Prescott, Rachel A., Valero-Jimenez, Ana M., Desvignes, Ludovic, O’Connor, Rebecca, Steppan, Claire, Devlin, Joseph C., Ivanova, Ellie, Herrera, Alberto, Schinlever, Austin, Loose, Paige, Ruggles, Kelly, Koralov, Sergei B., Anderson, Annaliesa S., Binder, Joseph, Dittmann, Meike
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2021
Materias:
Vaccines and Antiviral Agents
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139662/
https://www.ncbi.nlm.nih.gov/pubmed/33622961
http://dx.doi.org/10.1128/JVI.01819-20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139662/
https://www.ncbi.nlm.nih.gov/pubmed/33622961
http://dx.doi.org/10.1128/JVI.01819-20

Ejemplares similares